Shareholders approve Takeda’s $59bn takeover of ShireTakeda’s $59 billion acquisition of Shire has been backed by shareholders from both companies, clearing the way for Share XShareholders approve Takeda’s $59bn takeover of Shirehttps://pharmaphorum.com/news/shareholders-approve-takedas-59bn-takeover-of-shire/
Gene therapy firm BioMarin stages haemophilia musicalBioMarin Pharmaceutical has put on a stage musical to raise awareness about haemophilia, and determine whether creative expression Share XGene therapy firm BioMarin stages haemophilia musicalhttps://pharmaphorum.com/news/gene-therapy-firm-biomarin-stages-haemophilia-musical/
Takeda must sell gastro drug to merge with Shire – EU regulatorsEuropean regulators have officially rubber stamped Takeda’s $62 billion takeover of Shire, although the merged company will have Share XTakeda must sell gastro drug to merge with Shire – EU regulatorshttps://pharmaphorum.com/news/takeda-must-sell-gastro-drug-to-merge-with-shire-eu-regulators/
Takeda hurries $62bn Shire acquisition, calls investor vote next monthTakeda will hold an investor vote on its $62 billion acquisition of Shire next month, and aims to Share XTakeda hurries $62bn Shire acquisition, calls investor vote next monthhttps://pharmaphorum.com/news/takeda-hurries-62bn-shire-acquisition-calls-investor-vote-next-month/
Takeda CEO confident about Shire mergerTakeda’s CEO has said he is confident that its $62 billion acquisition of Shire will go ahead, despite Share XTakeda CEO confident about Shire mergerhttps://pharmaphorum.com/news/takeda-ceo-confident-about-shire-merger/
Takeda proposes selling Shire’s IBD treatment after mergerTakeda has proposed selling off a Shire treatment for inflammatory bowel disease when the companies merge next year, Share XTakeda proposes selling Shire’s IBD treatment after mergerhttps://pharmaphorum.com/news/takeda-proposes-selling-shires-ibd-treatment-after-merger/
FDA advisers back Shire constipation drugShire’s constipation drug prucalopride is moving closer to market – advisers to the FDA have just unanimously backed Share XFDA advisers back Shire constipation drughttps://pharmaphorum.com/news/fda-advisers-back-shire-constipation-drug/
FDA rejects Pharming’s Ruconest HAE label expansionThe FDA has rejected Pharming’s application to expand the licence of Ruconest, for a use as prophylaxis for Share XFDA rejects Pharming’s Ruconest HAE label expansionhttps://pharmaphorum.com/news/fda-rejects-pharmings-ruconest-hae-label-expansion/
Takeda could sell Shire eye care business after mergerTakeda could be considering selling Shire’s eye care business after their $62 billion merger next year to cut Share XTakeda could sell Shire eye care business after mergerhttps://pharmaphorum.com/news/takeda-shire-eye-care-business-merger/
